Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by Royal Bank of Canada

Royal Bank of Canada lessened its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 26.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 453,142 shares of the biotechnology company's stock after selling 167,127 shares during the period. Royal Bank of Canada owned about 0.16% of Exelixis worth $15,090,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Coppell Advisory Solutions LLC purchased a new position in shares of Exelixis during the 4th quarter worth approximately $25,000. Colonial Trust Co SC grew its holdings in shares of Exelixis by 616.9% during the 4th quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company's stock worth $30,000 after acquiring an additional 765 shares during the period. Principal Securities Inc. grew its holdings in shares of Exelixis by 62.8% during the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company's stock worth $32,000 after acquiring an additional 373 shares during the period. Kestra Investment Management LLC purchased a new position in shares of Exelixis during the 4th quarter worth approximately $39,000. Finally, Crowley Wealth Management Inc. purchased a new position in shares of Exelixis during the 4th quarter worth approximately $50,000. Hedge funds and other institutional investors own 85.27% of the company's stock.

Exelixis Trading Up 0.4%

Shares of NASDAQ:EXEL traded up $0.19 during trading on Thursday, reaching $42.60. The company's stock had a trading volume of 2,171,300 shares, compared to its average volume of 2,311,285. Exelixis, Inc. has a 12 month low of $20.14 and a 12 month high of $48.85. The firm's 50 day simple moving average is $38.25 and its two-hundred day simple moving average is $36.28. The stock has a market capitalization of $11.62 billion, a PE ratio of 24.07, a price-to-earnings-growth ratio of 1.13 and a beta of 0.25.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on EXEL. Stifel Nicolaus boosted their price target on Exelixis from $36.00 to $38.00 and gave the stock a "hold" rating in a research report on Wednesday, May 14th. JMP Securities reissued a "market outperform" rating and issued a $41.00 price target on shares of Exelixis in a research report on Thursday, April 17th. Piper Sandler boosted their price target on Exelixis from $37.00 to $38.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 12th. Barclays upped their price objective on Exelixis from $25.00 to $29.00 and gave the company an "equal weight" rating in a research report on Thursday, February 13th. Finally, Wells Fargo & Company reissued a "market outperform" rating on shares of Exelixis in a report on Thursday, April 17th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $38.94.

Insider Buying and Selling

In other Exelixis news, Director Tomas J. Heyman sold 4,544 shares of the stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $44.29, for a total value of $201,253.76. Following the completion of the sale, the director now owns 32,470 shares in the company, valued at approximately $1,438,096.30. This represents a 12.28% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Dana Aftab sold 1,508 shares of the stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $39.00, for a total transaction of $58,812.00. Following the completion of the sale, the executive vice president now directly owns 693,181 shares of the company's stock, valued at approximately $27,034,059. This trade represents a 0.22% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 459,276 shares of company stock worth $20,945,859 in the last 90 days. Insiders own 2.82% of the company's stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.